Clinical experience on diagnosis and treatment for malignancy originating from the dacryocyst.

OBJECTIVE: To summarize clinical experience on the diagnosis and treatment for malignancy originating from the dacryocyst. METHODS: We retrospectively analyzed clinicopathological data from 12 cases that were diagnosed with malignancy originating from the dacryocyst by histopathological examination in our hospital from 2007 to 2017. RESULTS: Of the 12 cases with malignancy originating from the dacryocyst, 7 were male and 5 were female, with a mean age of 53 years (range, 4-81). Clinical manifestations included a mass in the dacryocyst area in 12 cases, epiphora in 9 cases, pyoid tears in 2 cases, bloody tears in 3 cases, and redness and swelling in the dacryocyst area in 2 cases. Lymphoma occurred in six cases, malignant melanoma in three cases, embryonal rhabdomyosarcoma in one case, and squamous cell carcinoma in two cases. CONCLUSIONS: Misdiagnosis and missed diagnosis readily occur for malignancy originating from the dacryocyst because its clinical manifestations are diverse. For the suspected patients, it is necessary to perform related examinations. Individualized treatment should be adopted based on pathological types and specific conditions.

[Primary culture of human pterygia cells in vitro].

PURPOSE: To probe a selective method of isolate and culture of human pterygia cells in vitro. METHODS: Fifty primary pterygia were got by operation and cut to clips less than 1 x 1 mm2, segments were digested by collagenase II for 20 minutes and by trypsin for 10 minutes under 37 degrees C, and then centrifugated for 15 minutes by 1500 rpm. The collected cells were cultured in conditioned medium for endothelial cells. After purified by scrape and density gradient centrifugation, the cells were detected and identified by immunohistochemistry and electron microscope. RESULTS: The purity of cultured fibroblasts and endothelial cell type cells were more than 90%. CD31, CD34, and Weibel-Palade bodies were performed in these cells cytoplasm. CONCLUSION: We obtained the method of culturing human pterygia fibroblasts and endothelial cell type cells and it is a feasible and convenient approach.

In vivo and in vitro inhibitory effect of amniotic extraction on neovascularization.

PURPOSE: To prepare amniotic extraction (AE) and to test its antiangiogenic effect in vivo and in vitro. METHODS: AE was prepared and diluted to 50, 100, and 200 microg/mL concentrations. Alkali burn-induced corneal neovascularization (NV) was produced and topically treated with different concentrations of AE or 0.1% dexamethasone for 7 days. Normal saline was used as a control. Corneal NV was visualized by heart perfusion of Chinese ink and quantified as the percentage of corneal NV area to the whole corneal area. Human umbilical vein endothelial cells (HUVECs) were primarily cultured. The effects of AE on proliferation and tube formation of HUVECs were tested by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method and in vitro angiogenesis assay. Pigment epithelium-derived factor (PEDF) in AE was detected by Western blot. RESULTS: Relative corneal NV area in the control group was 56.6% +/- 9.9%, which was significantly reduced by 50 microg/mL AE (47.6% +/- 6.9%; P = 0.043) and 200 microg/mL AE (34.3% +/- 7.8%; P < 0.001) and by 0.1% dexamethasone (21.1% +/- 1.8%; P < 0.001). HUVEC cell proliferation was significantly decreased after treatment with AE at concentrations of 50 and 100 microg/mL compared with control (P = 0.036 and 0.001, respectively). The tube formation was significantly suppressed by 100 microg/mL AE (70.03% +/- 4.35%) compared with control (100% +/- 4.84%; P = 0.002). No expression of PEDF was detected in AE. CONCLUSION: AE inhibits NV induced by alkali burn. This effect may be elicited at least in part through the inhibiting activity of blood vessel endothelial cells and is not associated with PEDF.